Venture Partner, Brandon Capital
| Role | Organisation | Sources |
|---|---|---|
| ENA Respiratory | Brandon Capital portfolio, Brandon BioCatalyst portfolio | |
| Chief Executive (former) · Founder | Myricx Pharma | Brandon BioCatalyst portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Tue 17 Nov 2020), Brandon Capital portfolio (Mon 16 Nov 2020), Brandon BioCatalyst portfolio (Mon 16 Nov 2020) |
| Founder | Heptares | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Head of Respiratory Research (former) | GSK | Brandon BioCatalyst, Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Venture Partner | Brandon Capital | Forbes Australia, Brandon BioCatalyst, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Venture Partner (former) | Brandon Capital Partners | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Dr Roberto Solari. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Also Forbes Australia
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
UK biotech Myricx Pharma launched with a £4.5 million seed round from Sofinnova Partners and Brandon Capital to advance its NMT-inhibitor cancer drug discovery work.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio